Many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug instead of the usual 12, greatly reducing the risk of heart damage it sometimes can cause, a study suggests. It’s good news, but it comes nearly two decades after the drug first went on the market and many patients have suffered that side effect. The study was done in the United Kingdom and funded by UK government grants.